What is BioPoly?
BioPoly operates at the intersection of advanced material science and orthopedic surgery. The company specializes in the development of proprietary biomaterials that integrate hyaluronic acid with ultrahigh molecular weight polyethylene. This unique composition is engineered to address the critical needs of patients requiring joint repair, specifically targeting the great and lesser toe, radial head, and knee. By focusing on minimally invasive procedures, BioPoly provides healthcare professionals with high-performance implants designed to restore cartilage function and enhance patient mobility. The company's commitment to innovation in orthopedic implants positions it as a key contributor to the evolution of regenerative medicine and long-term joint health solutions.
How much funding has BioPoly raised?
BioPoly has raised a total of $3.7M across 2 funding rounds:
Private Equity
$1.7M
Private Equity
$2M
Private Equity (2016): $1.7M, investors not publicly disclosed
Private Equity (2019): $2M, investors not publicly disclosed
Key Investors in BioPoly
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for BioPoly?
With the successful closure of its latest financing round, BioPoly is well-positioned to scale its manufacturing capabilities and expand its clinical footprint. The strategic allocation of this capital will likely prioritize the acceleration of regulatory approvals for its next-generation implant portfolio and the expansion of its commercial distribution networks. As the company moves into this next phase of growth, the focus will remain on clinical validation and the broader adoption of its biomaterial technology within the orthopedic community. By maintaining a rigorous commitment to research and development, BioPoly aims to set new benchmarks for patient outcomes in cartilage repair, ensuring its long-term viability as a leader in the medical technology sector.
See full BioPoly company page
